Lista de obras -

A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma

artículo científico publicado en 2015

A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma

scientific article published on 24 November 2020

Adjuvant therapy for soft tissue sarcoma

artículo científico publicado en 2005

Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options

artículo científico

Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival.

artículo científico publicado en 2016

Chemotherapy in the management of osteosarcoma and Ewing's sarcoma

artículo científico publicado en 2007

Chordoma: the nonsarcoma primary bone tumor

artículo científico publicado en 2007

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

artículo científico publicado en 2013

Complications of a temozolomide overdose: a case report

artículo científico publicado en 2006

Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

artículo científico publicado en 2020

DR6 as a diagnostic and predictive biomarker in adult sarcoma

artículo científico publicado en 2012

Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results

artículo científico

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

artículo científico publicado en 2017

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

artículo científico publicado en 2015

Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors

artículo científico publicado en 2010

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

artículo científico publicado en 2009

Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.

artículo científico publicado en 2010

Ewing Sarcoma of the Kidney: Case Series and Literature Review of an Often Overlooked Entity in the Diagnosis of Primary Renal Tumors ⬇️

artículo científico publicado el 1 de febrero de 2013

Gastrointestinal stromal tumors, version 2.2014.

artículo científico publicado en 2014

Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation

artículo científico publicado en 2008

Histology-Specific Therapy for Advanced Soft Tissue Sarcoma and Benign Connective Tissue Tumors ⬇️

artículo científico publicado el 1 de septiembre de 2012

Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing

artículo científico publicado en 2013

Imaging and response in soft tissue sarcomas

artículo científico publicado en 2005

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials

artículo científico publicado en 2010

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors

artículo científico publicado en 2010

New targets for therapy of sarcoma

artículo científico publicado en 2008

Next generation sequencing of extraskeletal myxoid chondrosarcoma

artículo científico publicado en 2017

PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.

artículo científico publicado en 2016

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

artículo científico publicado en 2017

Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor

artículo científico publicado en 2016

Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.

artículo científico publicado en 2012

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

scientific article published on 18 May 2009

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas

artículo científico publicado en 2011

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

artículo científico publicado en 2011

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

artículo científico publicado en 2007

Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor

artículo científico publicado en 2016

Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung

scientific article published on 30 April 2020

SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy

artículo científico publicado en 2016

Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study

artículo científico

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

artículo científico publicado en 2009

Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome

artículo científico publicado en 2014

Selection of response criteria for clinical trials of sarcoma treatment

artículo científico publicado en 2008

So-called "inflammatory leiomyosarcoma'': a series of 3 cases providing additional insights into a rare entity

artículo científico publicado en 2005

Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

artículo científico publicado en 2016

Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines

artículo científico publicado en 2012

Soft tissue sarcoma, version 2.2014.

artículo científico publicado en 2014

Targeted therapy for dermatofibrosarcoma protuberans

artículo científico publicado en 2006

The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975–2004) ⬇️

artículo científico publicado el 28 de diciembre de 2009

Utility of positron emission tomography in sarcomas

artículo científico publicado en 2006

[F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults

artículo científico publicado en 2009

Lista de obras de

A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma

A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma

Adjuvant therapy for soft tissue sarcoma

Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options

Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival.

Chemotherapy in the management of osteosarcoma and Ewing's sarcoma

Chordoma: the nonsarcoma primary bone tumor

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

Complications of a temozolomide overdose: a case report

Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

DR6 as a diagnostic and predictive biomarker in adult sarcoma

Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.

Ewing Sarcoma of the Kidney: Case Series and Literature Review of an Often Overlooked Entity in the Diagnosis of Primary Renal Tumors ⬇️

Gastrointestinal stromal tumors, version 2.2014.

Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation

Histology-Specific Therapy for Advanced Soft Tissue Sarcoma and Benign Connective Tissue Tumors ⬇️

Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing

Imaging and response in soft tissue sarcomas

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors

New targets for therapy of sarcoma

Next generation sequencing of extraskeletal myxoid chondrosarcoma

PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor

Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor

Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung

SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy

Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome

Selection of response criteria for clinical trials of sarcoma treatment

So-called "inflammatory leiomyosarcoma'': a series of 3 cases providing additional insights into a rare entity

Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines

Soft tissue sarcoma, version 2.2014.

Targeted therapy for dermatofibrosarcoma protuberans

The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975–2004) ⬇️

Utility of positron emission tomography in sarcomas

[F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults